137 related articles for article (PubMed ID: 36063707)
21. Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons.
Koponen M; Tolppanen AM; Taipale H; Tanskanen A; Tiihonen J; Johnell K; Fastbom J; Ahonen R; Hartikainen S
Br J Psychiatry; 2015 Nov; 207(5):444-9. PubMed ID: 26450581
[TBL] [Abstract][Full Text] [Related]
22. Recent hospitalization and risk of antidepressant initiation in people with Parkinson's disease.
Hämäläinen I; Tiihonen M; Hartikainen S; Tolppanen AM
BMC Geriatr; 2022 Dec; 22(1):974. PubMed ID: 36528563
[TBL] [Abstract][Full Text] [Related]
23. Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis.
Rustembegovic A; Sofic E; Wichart I
Med Arh; 2006; 60(4):211-2. PubMed ID: 16761509
[TBL] [Abstract][Full Text] [Related]
24. Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine.
Osborn D; Marston L; Nazareth I; King MB; Petersen I; Walters K
Schizophr Res; 2017 May; 183():116-123. PubMed ID: 27884434
[TBL] [Abstract][Full Text] [Related]
25. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
Moisan J; Grégoire JP
Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
[TBL] [Abstract][Full Text] [Related]
26. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
Ballard C; Isaacson S; Mills R; Williams H; Corbett A; Coate B; Pahwa R; Rascol O; Burn DJ
J Am Med Dir Assoc; 2015 Oct; 16(10):898.e1-7. PubMed ID: 26239690
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of and indications for antipsychotic use in Parkinson's disease.
Bower JH; Grossardt BR; Rocca WA; Savica R
Mov Disord; 2018 Feb; 33(2):325-328. PubMed ID: 29278275
[TBL] [Abstract][Full Text] [Related]
28. Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease.
Koponen M; Lavikainen P; Taipale H; Tanskanen A; Tiihonen J; Hartikainen S; Tolppanen AM
J Am Med Dir Assoc; 2019 Dec; 20(12):1488-1494.e3. PubMed ID: 31466934
[TBL] [Abstract][Full Text] [Related]
29. Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Ronsley R; Nguyen D; Davidson J; Panagiotopoulos C
Can J Psychiatry; 2015 Oct; 60(10):441-50. PubMed ID: 26720191
[TBL] [Abstract][Full Text] [Related]
30. Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database.
Osborn DP; Petersen I; Beckley N; Walters K; Nazareth I; Hayes J
J Psychopharmacol; 2018 Oct; 32(10):1098-1103. PubMed ID: 29938561
[TBL] [Abstract][Full Text] [Related]
31. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.
Finkel S; Kozma C; Long S; Greenspan A; Mahmoud R; Baser O; Engelhart L
Int Psychogeriatr; 2005 Dec; 17(4):617-29. PubMed ID: 16202186
[TBL] [Abstract][Full Text] [Related]
32. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Wilby KJ; Johnson EG; Johnson HE; Ensom MHH
Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039
[TBL] [Abstract][Full Text] [Related]
33. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder.
Hassan M; Madhavan SS; Kalsekar ID; Makela EH; Rajagopalan K; Islam S; Kavookjian J; Miller LA
Ann Pharmacother; 2007 Nov; 41(11):1812-8. PubMed ID: 17925501
[TBL] [Abstract][Full Text] [Related]
34. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
35. Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: a nationwide register-based cohort study in Denmark.
Pasternak B; Svanström H; Ranthe MF; Melbye M; Hviid A
CNS Drugs; 2014 Oct; 28(10):963-73. PubMed ID: 24895158
[TBL] [Abstract][Full Text] [Related]
36. Atypical antipsychotic drugs in the treatment of Parkinson's disease.
Friedman JH
J Pharm Pract; 2011 Dec; 24(6):534-40. PubMed ID: 22095576
[TBL] [Abstract][Full Text] [Related]
37. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.
Fernandez HH; Friedman JH; Jacques C; Rosenfeld M
Mov Disord; 1999 May; 14(3):484-7. PubMed ID: 10348474
[TBL] [Abstract][Full Text] [Related]
38. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
39. Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer's Disease.
Koponen M; Taipale H; Lavikainen P; Tanskanen A; Tiihonen J; Tolppanen AM; Ahonen R; Hartikainen S
J Alzheimers Dis; 2017; 56(1):107-118. PubMed ID: 27935554
[TBL] [Abstract][Full Text] [Related]
40. Use of antipsychotic medications in patients with Parkinson's disease at Auckland City Hospital.
Bloomfield K; MacDonald L; Finucane G; Snow B; Roxburgh R
Intern Med J; 2012 Jul; 42(7):e151-6. PubMed ID: 21470354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
